Alembic Pharmaceuticals Ltd Q4 FY2023 Concall Summary

Key Takeaways

• A kitchen-sink quarter, deliberately so: A ₹1,150 crore asset impairment, a capitalization policy change, and the final Aleor amortization all landed in Q4, clearing the decks. Underneath, the India branded business grew 9% and ex-US generics grew 33%.
• US generics remains the open wound: Price erosion has slowed but persists in double digits, and management refused to give FY24 revenue guidance, calling it "very tough for me to predict."
• New plants are now a margin headwind, not a future promise: F2 and F3 commercialized in Q4, adding a ~₹60 crore quarterly cost run-rate that will pressure margins before sales ramp, a ramp management says will take "a year or two."
• India branded business is the reliable engine: Q4 growth of 9% (12% ex-Azithral) outpaced the industry, with specialty at 13% and acute ex-Azithral at 38%. Management expects to outpace industry growth again in FY24.
• What to watch next quarter: Whether the promised 10-product Q1 launch wave materializes, the pace of new plant sales ramp against the fixed ₹60 crore quarterly cost, and any further deterioration in US OSD margins.

The Kitchen-Sink Cleanup

• ₹1,150 crore impairment: The board recognized an impairment on capital work in progress for three new manufacturing facilities, with ₹677 crores written off in FY23 and a ₹474 crore provision created. The entire amount was withdrawn from general reserves (net of DTA), so there was no P&L impact.
• Capitalization policy reset: Effective 1 January 2023, the company stopped capitalizing pre-operative expenses for all new facilities, charging everything to the P&L. An additional ~₹65 crores was debited in Q4 under various heads as a result.
• Aleor amortization done: The final ₹11 crores of previously amortized R&D from the Aleor acquisition was expensed in Q4, bringing the full-year charge to ₹155 crores. No residual intangible assets remain on the books.
• Tax provision reversed: No income tax provision was required for the full year, so the provision made through Q3 was reversed in Q4, flattering the reported bottom line.
• Cash flow held up: Despite the impairments and policy changes, borrowing was almost unchanged versus March 2022. The entire capex program and ~₹200 crores of dividends were met from internal accruals.

US Generics: Erosion, Evasion, and a Margin Reset

• Price erosion has slowed but not stopped: Management confirmed erosion is still in double digits, though less severe than a year ago. The structural driver is excess Indian manufacturing capacity aimed at the US market, compounded by some competitors deprioritizing the US and regulatory issues at other firms.
• Q4 revenue not comparable: US generics sales of ₹354 crores in Q4 cannot be compared to the prior-year quarter, which benefited from exceptional distributor stocking during a 3PL transition.
• Management refused to guide: When asked for FY24 US revenue expectations from the current \$180-200 million base, management declined: "we don't give a forward guidance" and "very tough for me to predict." Therapy-wise segmentation for US launches was also declined.
• The legacy margin pool has shrunk: Even before the new plant start-ups, the fundamental margins in the legacy US OSD business have come down from the elevated levels seen during shortage periods. That base erosion is now a permanent drag on consolidated margins.
• FY24 launch pipeline: 20-25 product launches planned for the full year, with Q1 carrying a heavier load of up to 10 products. The mix is roughly 10-12 oral solids, with the rest in ophthalmics and injectables. ANDA filings are targeted at 15-20 per year.

Pranav Amin: "I believe there will continue to be erosion because fundamentally there's just a lot more capacity for the US market from India than is warranted and that's what's causing this."

New Plants: From Capex to Opex

• F2 and F3 commercialized: Both plants dispatched their first products in Q4. F2 (oncology) has received an EIR and five final approvals including onco OSD. F3 has had three final approvals to date, with a March USFDA inspection yielding two observations.
• F4 and Derma progress: The new oral solid facility F4 was inspected in December with five observations and has two product approvals so far. The Derma facility had a March inspection with zero 483 observations.
• The cost clock is now ticking: With commercialization, the plants shift from being sites for exhibit batches and filings to generating operating expenses. Management pegged the additional cost run-rate at ~₹60 crores per quarter, which will pressure margins until sales ramp.
• Ramp is gradual, not step-change: The plants will start with 5-7 products, scale to 10 in the second half of FY24, and reach 25 products only in FY25. Full optimal utilization is "a year or two" away.
• Capex is winding down: FY24 capex is guided below ₹250 crores, focused on de-bottlenecking API capacities, a solar power investment to reduce electricity costs, and early-stage work on a new facility for the India branded business.

India Branded: Outpacing the Market

• Broad-based growth: Q4 India branded revenue grew 9% to ₹490 crores, or 12% excluding Azithral. Full-year growth was 7% (₹2,063 crores), or 13% excluding Azithral and Alcibute.
• Specialty led, acute surged: Specialty grew 13% in Q4 versus the industry's 12%, driven by gynecology, anti-diabetic, ophthalmology, and orthopedics. The acute segment grew 23% overall and 38% ex-Azithral, well ahead of the industry's 28%. Respiratory was a standout at 38% versus the industry's 28%.
• Isofit launch validated: The product was the second-best launch in the industry by IMS among 3,072 new launches over 12 months, generating ₹28 crores in its first year.
• Turnaround bets placed: Cardiology, gastroenterology, and gynecology underperformed in FY23. Management has taken operational and strategic interventions and expects growth from these therapies to "start kicking in this year."
• Animal health momentum: The segment grew 15% in Q4 and 21% for the full year.
• FY24 ambition: Management expects to outpace industry growth, with a range from matching the market to growing 4-5 points faster, driven by new launches, some price increases, and volume.

Ex-US Generics and API: The Quiet Contributors

• Ex-US generics surged 33% in Q4 and grew 10% for the full year, both from a high base. Management expects ~10-12% growth in FY24.
• API grew 41% in Q4 and 24% for FY23. Growth is volume-led, not price-driven, supported by long-term contracts and freed-up capacity. Pricing pressure persists as Chinese intermediate supply constraints ease.
• FY24 API growth pegged at ~10%.

Pranav Amin: "Lot of the growth is not due to pricing. It's due to volume growth."

Margins: The 15% Anchor

• New plant costs are the structural drag: With F2 and F3 now commercialized, the ~₹60 crore quarterly opex run-rate is locked in, while sales from those plants will ramp only gradually.
• US legacy margin decline compounds the pressure: The fundamental margin pool in the legacy US OSD business has shrunk from the elevated levels seen during shortage periods, dragging down consolidated profitability.
• Input costs mixed: Some pressure persists on packing and raw material costs, though easing oil prices may help. Energy costs are rising due to state electricity board rate hikes and increased unit consumption from the new facilities. A solar power investment is expected to deliver savings from H2 FY24.
• R&D optimization underway: Ex-Aleor R&D was 9% of sales in Q4 and 10% for FY23. Management will continue optimizing, particularly on oral solid dosages, with annualized spend guided at ~₹500-525 crores and a mix shift toward injectables.
• Opex growth guided at ~10% from a ~₹2,000 crore base, implying ~₹2,200 crores for FY24.

Mitanshu Shah: "I would say that a number around 15% would be a right number to go with."

Guidance & Commitments

Key Metrics